Novartis to acquire MorphoSys for €2.7bn.

Novartis, a pharmaceutical company, agreed to acquire MorphoSys, a biopharmaceutical company, for €2.7bn. “We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer. With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise. Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realize the full impact and value of their investigational medicines for patients with unmet needs,” Shreeram Aradhye, Novartis President and Chief Medical Officer.